ClearBridge Investments
BCAX

ClearBridge Investments’s Bicara Therapeutics BCAX Stock Holding History

ClearBridge Investments’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.6M Buy
289,785
+564
+0.2% +$12.6K 0.01% 519
2026
Q1 		$5.75M Sell
289,221
-9,541
-3% -$164K 0.01% 542
2025
Q4 		$5.03M Sell
298,762
-25,559
-8% -$437K ﹤0.01% 574
2025
Q3 		$5.12M Buy
+324,321
New +$3.63M ﹤0.01% 593

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ClearBridge Investments's BCAX Position: Q2 2026 in Review

ClearBridge Investments increased its Bicara Therapeutics (BCAX) stake by 0.2% in Q2 2026, buying an estimated $12.6K and bringing the position to 289,785 shares worth $8.6M. The position accounts for 0.01% of the portfolio, ranked #519.

ClearBridge Investments first reported a position in BCAX in Q3 2025 and has held it in 4 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • ClearBridge Investments held 289,785 shares of Bicara Therapeutics worth $8.6M as of Q2 2026.
  • ClearBridge Investments bought 564 Bicara Therapeutics shares in Q2 2026, an estimated $12.6K.
  • Bicara Therapeutics made up 0.01% of ClearBridge Investments's portfolio in Q2 2026, its #519 holding.
  • ClearBridge Investments first reported a position in Bicara Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on ClearBridge Investments's 13F filing for Q2 2026, filed 13 Aug 2026.